| |
Relative risk of recurrence
| |
Relative risk of death
|
---|
| |
Univariate
|
Multivariate
| |
Univariate
|
Multivariate
|
---|
|
n(events)
|
RR(95%CI
|
RR(95%CI
|
n(events)
|
RR(95%CI)
|
RR(95%CI)
|
---|
Age
| | | | | | |
Continuous
|
255(47)
|
1.01(0.97-1.05)
| |
255(53)
|
1.09(1.04-1.13)
|
1.07(1.02-1.12)
|
Gender
| | | | | | |
Female
|
132(21)
|
1.00
| |
132(18)
|
1.00
|
1.00
|
Male
|
123(26)
|
1.51(0.85-2.69)
| | |
2.60(1.47-4.61)
|
2.37(1.22-4.57)
|
Clark level
| | | | | | |
II
|
93(5)
|
1.00
|
1.00
|
93(13)
|
1.00
| |
III
|
103(21)
|
4.39(1.65-11.65)
|
1.93(0.51-7.26)
|
103(21)
|
1.70(0.85-3.40)
| |
IV-V
|
51(21)
|
9.99(3.76-26.55)
|
1.02(0.24-4.34)
|
51(18)
|
3.04(1.49-6.22)
| |
Breslow
| | | | | | |
Continuous
|
248(47)
|
1.07(1.03-1.11)
| |
248(53)
|
1.07(1.03-1.12)
| |
Subtype
| | | | | | |
SSM, LMM, Other
|
195(22)
|
1.00
| |
195(30)
|
1.00
|
1.00
|
Nodular
|
53(24)
|
5.63(3.15-10.08)
| |
53(22)
|
3.86(2.21-6.74)
|
2.32(1.20-4.94)
|
Ulceration
| | | | | | |
No
|
213(30)
|
1.00
| |
214(35)
|
1.00
|
1.00
|
Yes
|
35(16)
|
5.80(3.12-10.77)
| |
35(17)
|
6.29(3.46-11.45)
|
3.52(1.63-7.61)
|
Lymphocytic
| | | | | | |
infiltrate
| | | | | | |
0-1
|
72(20)
|
1.00
| |
72(22)
|
1.00
|
1.00
|
2-3
|
176(76)
|
0.43(0.24-0.78)
| |
176(30)
|
0.46(0.26-0.79)
|
0.55(0.30-1.00)
|
Clinical stage
| | | | | | |
I
|
179(12)
|
1.00
|
1.00
|
179(22)
|
1.00
| |
II-IV
|
28(13)
|
15.02(6.39-35.30)
|
7.36(2.47-21.47)
|
28(11)
|
6.48(3.05-13.73)
| |
Mitotic count
| | | | | | |
< 1/mm2
|
131(7)
|
1.00
|
1.00
|
131(17)
|
1.00
| |
> = 1/mm2
|
122(40)
|
7.99(3.56-17.80)
|
2.86(0.96-8.47)
|
122(36)
|
1.26(1.19-1.34)
| |
Vascular invasion
| | | | | | |
No
|
232(35)
|
1.00
|
1.00
|
232(42)
|
1.00
|
1.00
|
Yes
|
14(11)
|
9.25(4.67-18.35)
|
3.40(1.60-7.20)
|
14(9)
|
4.88(2.37-10.08)
|
3.81(1.62-8.97)
|
RBM3 intensity
| | | | | | |
0-2
|
95(24)
|
1.00
|
1.00
|
95(29)
|
1.00
|
1.00
|
3
|
120(20)
|
0.50 (0.27-0.91)
|
0.87(0.46-1.66)
|
120(20)
|
0.36(0.20-0.64)
|
0.33(0.18-0.61)
|
- The number of cases in the multivariate analysis is equal to the number of cases evaluated for RBM3 expression (n = 215).